PMC:7033706 / 6794-7331
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 183 | 229-230 | Gene | denotes | S | Gene:43740568 |
| 184 | 23-31 | Species | denotes | SARS-CoV | Tax:694009 |
| 185 | 36-44 | Species | denotes | MERS-CoV | Tax:1335626 |
| 186 | 219-228 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 187 | 284-293 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 188 | 386-394 | Species | denotes | SARS-CoV | Tax:694009 |
| 189 | 402-410 | Species | denotes | MERS-CoV | Tax:1335626 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T22 | 163-170 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T30 | 23-31 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T31 | 372-375 | Disease | denotes | NTD | http://purl.obolibrary.org/obo/MONDO_0008449|http://purl.obolibrary.org/obo/MONDO_0018075 |
| T33 | 386-394 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T91 | 147-149 | http://purl.obolibrary.org/obo/CLO_0050050 | denotes | S1 |
| T92 | 256-257 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T93 | 380-382 | http://purl.obolibrary.org/obo/CLO_0008922 | denotes | S2 |
| T94 | 380-382 | http://purl.obolibrary.org/obo/CLO_0050052 | denotes | S2 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T50 | 163-170 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T51 | 380-382 | Chemical | denotes | S2 | http://purl.obolibrary.org/obo/CHEBI_29387 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T37 | 0-203 | Sentence | denotes | The recently developed SARS-CoV and MERS-CoV neutralizing monoclonal antibodies (mAbs) and nanobodies with protective efficacy are specific to the S1 subunit of S protein, particularly the RBD [5,89–10]. |
| T38 | 204-312 | Sentence | denotes | Therefore, the 2019-nCoV S-RBD is anticipated to be a key target for developing 2019-nCoV neutralizing mAbs. |
| T39 | 313-537 | Sentence | denotes | The neutralizing mAbs targeting non-RBD regions, including NTD and S2 of SARS-CoV and/or MERS-CoV S could also be identified [5,8,11,12], although their neutralizing potency is generally lower than that of RBD-specific mAbs. |